Navigation Links
CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
Date:3/15/2013

Fayetteville, AR (PRWEB) March 15, 2013

Geoffrey Dalbow has recently joined Cardiowise, Inc. as Chief Technology Officer. His background includes substantial leadership experience in the highly competitive area of medical technology. Through the application and optimization of emerging imaging technologies, he has delivered solutions that improved health care quality, safety and efficiencies, while reducing the cost of care. During his career, Mr. Dalbow has directed multiple research and development efforts delivering a broad range of products and solutions to improve healthcare. He managed and secured more than 80 patents for R2 Technology in the area of Computer-Aided Detection technology. His business experience is international in scope and includes India, China and the Middle East as well as South America.

Mr. Dalbow comes to CardioWise from CMS, Roper Industries where he was recently employed as the CTO and Director of Business Development. Prior to Roper, Geoffrey was the Director of Research and Development for Philips Medical Systems. Previous to that, Dalbow and a team of technology experts established R2 Technology, where he directed the research and development of medical solutions for computer-aided detection and diagnosis of cancer. In only three years, in his position as CTO, the company was taken from startup to market share leader and was successfully sold. Prior to R2 Technologies, Mr. Dalbow held several leadership positions with Varian Medical Systems. His wealth of imaging and product development expertise provides Cardiowise with the leadership needed to build the company’s innovative development and growth platform.

Mr. Dalbow received his Bachelor of Science from Carnegie Mellon University and completed numerous courses towards his Ph.D. in Medical Physics at the University of Pittsburgh. He has held management positions in several companies on the Forbes Best Managed Companies Top 100 Li
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
3. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
4. United States Rocket Academy Welcomes XCOR Aerospace to Texas
5. Chiltern Welcomes Drs. Dieter Seitz-Tutter And Alexandra Adams
6. Elsevier Welcomes New Editor-in-Chief for European Urology
7. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
8. ABC Welcomes New Advisory Board Members
9. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
10. John Saltamartine to Lead Operations as VR Laboratories Chief Operating Officer
11. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... by George Washington University Professor Tianshu Li provide ... small droplets is strongly size-dependent, an important conclusion ... formation of ice at the nanoscale is a ... has important implications for climate research and other ... supercooled water is generally initiated by a process ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Mass., April 21 NxStage Medical, Inc. (Nasdaq: ... products, today announced plans to release its financial results ... Friday, May 8, 2009 before the opening of the ... 9:00 a.m. Eastern Time on Friday, May 8, 2009 ...
... April 21 At the Annual General Meeting of ... all the motions proposed by the Board of Directors. ... for the business year 2008, an increase of 25% ... of the share capital to CHF 9,459,984.90 through the ...
... to FollowTHE WOODLANDS, Texas, April 21 Lexicon Pharmaceuticals, ... first quarter 2009 financial results on Tuesday, April 28, ... will hold a conference call to discuss its clinical ... at 11:00 a.m. Eastern Time on April 28, 2009. ...
Cached Biology Technology:NxStage to Report First Quarter 2009 Financial Results 2Syngenta holds Annual General Meeting 2Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009 2
(Date:5/21/2013)... Illinois at Chicago College of Medicine will study gender differences ... main energy source -- and how changes in fat metabolism ... million, 4-year grant from the National Heart, Lung and Blood ... fuel for energy. These changes may play a major role ... men and women, says E. Douglas Lewandowski, director of the ...
(Date:5/21/2013)... few decades, scientists have developed many devices that can ... While generally effective, each of these treatments has drawbacks, ... study from MIT analyzes the potential usefulness of a ... and drug-releasing stents, but may pose fewer risks. With ... artery for only a brief period, during which it ...
(Date:5/21/2013)... 2013 Royal Philips Electronics (NYSE: PHG, AEX: ... portable ultrasound with Philips, industry leading Live 3D TEE, ... xMATRIX with available Live 3D TEE and ICE will ... the EuroPCR, official meeting for the European Association of ... its launch in 2012, Philips CX50 xMATRIX has been ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... hallmark of type 2 diabetes and a condition often ... to muscle wasting and severe fat loss that accompanies ... an animal study, a diabetes drug that promotes insulin ... loss, the main consequences of a syndrome called cachexia, ...
... RICHLAND, Wash. -- An analytical chemist at the Department ... with a National Institutes of Health Director,s New Innovator ... make new research and clinical diagnostic tools that are ... The award, which comes with a $1.5 million, ...
... Carolina at Chapel Hill School of Medicine and the ... from the National Institutes of Health (NIH) aimed at ... Ph.D., and Mark Zylka, Ph.D., have received "Transformative" RO1 ... the UNC College of Arts and Sciences, has been ...
Cached Biology News:Diabetes drug shows promise in fighting lethal cancer complication 2Diabetes drug shows promise in fighting lethal cancer complication 3PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3UNC scientists garner new NIH awards for high risk, transformative research 2UNC scientists garner new NIH awards for high risk, transformative research 3UNC scientists garner new NIH awards for high risk, transformative research 4
... LUMIstar OPTIMA is a fully automated ... for the widest possible range of ... Reporter gene assays luciferase, -galactosidase, gene ... esters, dioxetanes..) Luminescent Immunoassays ...
... dispensers save space and organize gloves, ... garb. They are the perfect benchtop ... in labs, processing and manufacturing. Clear ... the particles they attract. Open-slot design ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... except that it uses a deep-UV deuterium bulb, ... comes with a shutter (controlled via a TTL ... Light Source produces a powerful, stable output from ... light source are available, providing a wavelength range ...
Biology Products: